Rallybio - Bathi saben saham sajroning taun lumaku RLYB

Rallybio Corporation (RLYB) is developing innovative therapies for fetuses and newborns, leveraging research centers in Connecticut and external CDMO facilities. On GURU.Markets, the history of YoY (ttm) EPS percentage changes captures profit dynamics, where 279.90 serves as the final level marker. Specialization in orphan diseases guarantees the company long-term monopoly status and lifelong patient demand for its medications.
Rallybio Corporation - rincian analitis lan metrik utama (RLYB)

This indicator tracks the percentage change in earnings per share over the last twelve months relative to the same period last year, determining the business's profitability trend. By analyzing the annual EPS growth based on TTM financial statements, an investor assesses the efficiency of capital investments in the elite research staff of Rallybio Corporation (RLYB), whose developments in the field of rare diseases are expected to convert into financial results.